Should I buy or sell ContraFect stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CFRX shares. View CFRX analyst ratings or view top-rated stocks .

What is ContraFect's stock price target for 2024?

1 analysts have issued 1-year target prices for ContraFect's shares. Their CFRX share price targets range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 6,464.6% from the stock's current price. View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts .

How have CFRX shares performed in 2023?

ContraFect's stock was trading at $7.68 on January 1st, 2023. Since then, CFRX shares have decreased by 99.4% and is now trading at $0.0457. View the best growth stocks for 2023 here .

Are investors shorting ContraFect?

ContraFect saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 59,600 shares, a decrease of 48.6% from the October 15th total of 116,000 shares. Based on an average daily volume of 217,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.1% of the company's stock are sold short. View ContraFect's Short Interest .

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) announced its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.16.

When did ContraFect's stock split?

ContraFect shares reverse split on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX) , Inovio Pharmaceuticals (INO) , Verastem (VSTM) , Vaxart (VXRT) , Matinas BioPharma (MTNB) , VBI Vaccines (VBIV) , Novavax (NVAX) , Cidara Therapeutics (CDTX) , Gilead Sciences (GILD) and Dynavax Technologies (DVAX) .

Who are ContraFect's major shareholders?

ContraFect's stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.44%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of ContraFect?

Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ContraFect Stock Price, News & Analysis (NASDAQ:CFRX)

$0.05

-0.02 (-27.95%)

(As of 02:44 PM ET)

Compare

Today's Range: $0.05
▼
$0.06
50-Day Range: $0.05
▼
$0.58
52-Week Range: $0.04
▼
$13.02

Volume: 504,419 shs
Average Volume: 1.39 million shs
Market Capitalization: $535,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

ContraFect MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 6,464.6% Upside
$3.00 Price Target
Short Interest: Healthy
1.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.44) to ($1.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
ContraFect has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, ContraFect has a forecasted upside of 6,464.6% from its current price of $0.05.
Amount of Analyst Coverage
ContraFect has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.09% of the float of ContraFect has been sold short.
Short Interest Ratio / Days to Cover
ContraFect has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ContraFect has recently decreased by 48.62%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ContraFect does not currently pay a dividend.
Dividend Growth
ContraFect does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CFRX.

1.1

News and Social Media Coverage

Search Interest
3 people have searched for CFRX on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added ContraFect to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ContraFect insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.62% of the stock of ContraFect is held by insiders.
Percentage Held by Institutions
Only 7.85% of the stock of ContraFect is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ContraFect are expected to grow in the coming year, from ($3.44) to ($1.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ContraFect is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ContraFect is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About ContraFect Stock (NASDAQ:CFRX)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

CFRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CFRX Stock News Headlines

November 28, 2023 | americanbankingnews.com

ContraFect (NASDAQ:CFRX) Stock Price Crosses Below 50-Day Moving Average of $0.33

November 28, 2023 | americanbankingnews.com

ContraFect (NASDAQ:CFRX) Earns Sell Rating from Analysts at StockNews.com

December 5, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 19, 2023 | morningstar.com

ContraFect Corp CFRX

November 14, 2023 | washingtonpost.com

ContraFect: Q3 Earnings Snapshot

October 23, 2023 | benzinga.com

Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket

October 16, 2023 | msn.com

Why Is ContraFect (CFRX) Stock Up 23% Today?

October 16, 2023 | finance.yahoo.com

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

December 5, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

October 10, 2023 | benzinga.com

Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

September 21, 2023 | finance.yahoo.com

CFRX: IND Application for CF-370 Submitted to FDA…

September 19, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)

September 19, 2023 | finance.yahoo.com

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

September 18, 2023 | finance.yahoo.com

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

August 28, 2023 | finance.yahoo.com

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

August 17, 2023 | finance.yahoo.com

CFRX: CF-370 IND to be Filed in 3Q23…

August 15, 2023 | markets.businessinsider.com

ContraFect (CFRX) Receives a Buy from Maxim Group

August 14, 2023 | sfgate.com

ContraFect: Q2 Earnings Snapshot

August 14, 2023 | finance.yahoo.com

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

July 25, 2023 | money.usnews.com

ContraFect Corp

July 6, 2023 | msn.com

ContraFect (CFRX) Price Target Decreased by 97.37% to 5.10

June 27, 2023 | msn.com

ContraFect enters a warrant exercise transaction for $9.6M

June 27, 2023 | finance.yahoo.com

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

June 22, 2023 | marketwatch.com

8-K: CONTRAFECT Corp

June 22, 2023 | finance.yahoo.com

CFRX: CF-370 Effective in Rabbit Lung Infection Model Caused by Klebsiella Pneumoniae…

June 20, 2023 | finance.yahoo.com

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

June 9, 2023 | msn.com

ContraFect Gains with Key Data Presentation Set for Next Week

See More Headlines

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CFRX
CUSIP: N/A
CIK: 1478069
Web: www.contrafect.com
Phone: (914) 207-2300
Fax: N/A
Employees: 23
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $3.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +4,794.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($19.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,150,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -138.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.53
Quick Ratio: 0.53

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($19.92) per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 10,700,000
Free Float: 10,639,000
Market Cap: $655,910.00
Optionable: Not Optionable
Beta: 0.29

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Roger James Pomerantz FACP (Age 66)
M.D., Chairman, CEO & President
Comp: $970.72k
Mr. Michael Messinger CPA (Age 48)
Chief Financial Officer
Comp: $543.14k
Ms. Natalie Bogdanos J.D. (Age 54)
General Counsel, Corporate Secretary & Data Protection Officer
Comp: $531.2k
Mr. Matthew Salamone P.H.R.
SPHR, Vice President of Human Resources
Dr. Gary Woodnutt (Age 66)
Senior Vice President of Translational Sciences & Preclinical Development
Dr. William Garrett Nichols M.D. (Age 54)
M.S., Interim Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Bought 419,258 shares on 11/15/2023
Ownership: 4.439%

View All Institutional Transactions

CFRX Stock Analysis - Frequently Asked Questions

Should I buy or sell ContraFect stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings or view top-rated stocks.
What is ContraFect's stock price target for 2024?: 1 analysts have issued 1-year target prices for ContraFect's shares. Their CFRX share price targets range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 6,464.6% from the stock's current price.
View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts.
How have CFRX shares performed in 2023?: ContraFect's stock was trading at $7.68 on January 1st, 2023. Since then, CFRX shares have decreased by 99.4% and is now trading at $0.0457.
View the best growth stocks for 2023 here.
Are investors shorting ContraFect?: ContraFect saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 59,600 shares, a decrease of 48.6% from the October 15th total of 116,000 shares. Based on an average daily volume of 217,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.1% of the company's stock are sold short.
View ContraFect's Short Interest.
How were ContraFect's earnings last quarter?: ContraFect Co. (NASDAQ:CFRX) announced its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.16.

When did ContraFect's stock split?: ContraFect shares reverse split on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
What other stocks do shareholders of ContraFect own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).
Who are ContraFect's major shareholders?: ContraFect's stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.44%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of ContraFect?: Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CFRX) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial